secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001193125-23-063737
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Q4 2022 net loss $45.8M, cash $424.6M; THRIVE Ph3 enrolled
-------------------------------------------------------------------

- Net loss $45.8M in Q4 2022 vs $28.9M in Q4 2021; R&D expense $39.3M vs $22.4M.
- Cash, equivalents & short-term investments $424.6M as of Dec 31, 2022; runway into H2 2025.
- First patient enrolled in THRIVE Phase 3 trial of VRDN-001 for active TED; topline mid-2024.
- Initial proof-of-concept data for VRDN-001 in chronic TED expected Q2 2023.
- Appointed Scott Myers as President and CEO in February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/0001193125-23-063737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/d478193d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-063737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer